TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30667591
Drug: Twice-daily immediate-release
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily immediate-release tacrolimus capsules (IR-Tac) 0.10-0.15 mg/kg/day
Study: 30667591
Drug: Once-daily extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily extended-release tacrolimus tablets (LCPT)
Study: 30667591
Drug: Twice-daily immediate-release
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily immediate-release tacrolimus capsules (IR-Tac)
Study: 30413507
Drug: Digital treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital treatment programme (Joint Academy) for 3 months
Study: 30413507
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (BOA) for 3 months
Study: 25191967
Drug: Methacholine (MCh)
DrugBank: Methacholine (DB06709)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methacholine (MCh) challenge with deep inspirations (DIs) taken immediately after the last dose
Study: 25191967
Drug: Methacholine (MCh)
DrugBank: Methacholine (DB06709)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methacholine (MCh) challenge with DIs taken 30 minutes after the last dose
Study: 22718089
Drug: bivalent rLP2086
Normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bivalent rLP2086 vaccine (200 μg dose)
Study: 22718089
Drug: bivalent rLP2086
Normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bivalent rLP2086 vaccine (60 μg dose)
Study: 22718089
Drug: bivalent rLP2086
Normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bivalent rLP2086 vaccine (20 μg dose)
Study: 22718089
Drug: bivalent rLP2086
Normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bivalent rLP2086 vaccine
Study: 22718089
Drug: hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: hepatitis A vaccine/placebo control
Study: 16149143
Drug: High-dose interferon-α2b
Normalized name: Interferon α-2b
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose interferon-α2b (10 MU daily for 3 weeks, then 5 MU/TIW) plus ribavirin (1,000-1,200 mg/d) for 21 weeks, continued until week 48 if negative HCV RNA PCR.
Study: 7703820
Drug: Individual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual treatment for partners of drinkers
Study: 7703820
Drug: Group treatment
Normalized name: Allergenic Extracts Intradermal Kit [9 SO. GRASS GROUP TREATMENT SET]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group treatment for partners of drinkers
Study: 7703820
Drug: No-treatment waiting
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment waiting list control
Study: 786665
Drug: Acetylcysteine 600
Normalized name: acetylcysteine 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcysteine 600 mg daily, 3 days a week for 6 months
Study: 31995214
Drug: Behavioral health‐virtual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral health‐virtual patient navigation program (video contact in ED and telephonic outreach 24 to 72 hours after discharge, then weekly for up to 45 days)
Study: 22594305
Drug: Rabeprazole sodium
Normalized name: Rabeprazole Sodium
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rabeprazole sodium (20 mg daily) for 4 weeks
Study: 19383241
Drug: Sinus rhythm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinus rhythm control with aspirin (group 1)
Study: 19383241
Drug: Sinus rhythm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinus rhythm control with warfarin (group 2)
Study: 17447980
Drug: 5% calcipotriol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% calcipotriol cream
Study: 15953083
Drug: Moisturizing cream
Normalized name: MOISTURIZING CREAM
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moisturizing cream
Study: 8203766
Drug: EGb 761
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGb 761 (320 mg per day for four weeks)
Study: 28903476
Drug: AdVEGF‐DΔNΔC gene
Approvals — FDA: no, EMA: no, PMDA: no
Description: AdVEGF‐DΔNΔC gene therapy
Study: 12589843
Drug: ME inflation
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: ME inflation and antibiotics (oral Amoxicillin 500 mg 3/day) for 10 days
Study: 9113191
Drug: Ketamine 50
Normalized name: ketamine 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 50 mg x 4 per day dissolved in juice
Study: 8272492
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream 5% applied for 15 to 30 minutes
Study: 3476505
Drug: 150 micrograms/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 micrograms/ml sanguinaria and 0.2% zinc chloride (Rinse B)
Study: 3476505
Drug: 300 micrograms/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 micrograms/ml sanguinaria and no zinc chloride (Rinse C)
Study: 3476505
Drug: 300 micrograms/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 micrograms/ml sanguinaria and 0.2% zinc chloride (Rinse D)
Study: 3476505
Drug: Placebo oral
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral rinse (Rinse A)
Study: 21968596
Drug: 3T (triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3T (triple target treatment)
Study: 18477086
Drug: Ropivacaine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 10 mg/ml
Study: 18477086
Drug: Levobupivacaine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 7.5 mg/ml
Study: 9851651
Drug: Gabapentin 500
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 500 mg/day for 6 months (Group A)
Study: 9851651
Drug: Gabapentin 1000
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 1000 mg/day for 6 months (Group B)
Study: 9851651
Drug: Gabapentin 500
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 500 mg/day for 6 months followed by 1000 mg/day for 6 months (Group C)
Study: 9851651
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Group D) receiving only symptomatic treatment
Study: 2529986
Drug: Selenium supplement
Normalized name: Selenium supplement
DrugBank: Selenious acid (DB11127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplement (150 micrograms/d for 21 days)
Study: 6104295
Drug: Trimazosin (TMZ)
Normalized name: TMZ
DrugBank: Trimazosin (DB09206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimazosin (TMZ) treatment for up to 52 weeks
Study: 26786567
Drug: 0.5% C.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% C. indicum water extract cosmetic cream
Study: 26786567
Drug: Placebo (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (no extract) cosmetic cream
Study: 25180636
Drug: Collagen implant
Normalized name: Collagen implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen implant with gentamicin sulphate (Collatamp(®))
Study: 22577263
Drug: Topical tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tacrolimus monotherapy
Study: 17633971
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg zoledronic acid annually
Study: 11786572
Drug: G-CSF (lenograstim)
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (lenograstim) 5 microg/kg/d from day 7 until ANC > or = 500/microL sustained over 48 hours after two induction courses.
Study: 11786572
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no G-CSF).
Study: 26138423
Drug: Invasive‐noninvasive sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive‐noninvasive sequential mechanical ventilation (MV)
Study: 15896827
Drug: valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan 80 mg/day for 8 weeks
Study: 14998786
Drug: Arginine boluses
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine boluses (1-60 mg/kg) injected intravenously at 29-min intervals for 120 min
Study: 7977853
Drug: Hyperinsulinemic hypoglycemia
Normalized name: Drugs for treatment of hypoglycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperinsulinemic hypoglycemia (H; 2.5 mmol/l)
Study: 7977853
Drug: Hyperinsulinemic euglycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperinsulinemic euglycemia (E; 4.5 mmol/l)
Study: 2531510
Drug: ISDN (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISDN (standard release formulation) 40 mg administered 6 times daily (240 mg total)
Study: 2531510
Drug: ISDN (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISDN (40 mg) administered 4 times daily
Study: 2531510
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of glycerol trinitrate (3 mg/h)
Study: 2531510
Drug: Oral ISDN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ISDN (standard release formulation) administered 4-6 times daily
Study: 2531510
Drug: Nitrate therapy
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate therapy providing constant doses over time (e.g. I.V. nitroglycerin)
Study: 26186450
Drug: S. frutescens
Approvals — FDA: no, EMA: no, PMDA: no
Description: S. frutescens 1,200 mg twice daily
Study: 9286131
Drug: Short-term psychiatric
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term psychiatric inpatient treatment in another hospital.
Study: 8329826
Drug: Low-dose GHRH(1-29)-NH2
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose GHRH(1-29)-NH2 (LD group; n = 15) at 30 micrograms/kg/day s.c. in three daily doses
Study: 8329826
Drug: High-dose GHRH(1-29)-NH2
Normalized name: GHRH(1-44)NH2
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose GHRH(1-29)-NH2 (HD group; n = 12) at 60 micrograms/kg/day s.c. in three daily doses
Study: 8329826
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH group; n = 16) at 0.1 IU/kg/day s.c. once daily
Study: 3329851
Drug: FD group
Approvals — FDA: no, EMA: no, PMDA: no
Description: FD group (154 micrograms fentanyl plus 5.5 mg droperidol i.v.)
Study: 3329851
Drug: FV group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: FV group (127 micrograms fentanyl plus 6.7 mg Valium)
Study: 27644633
Drug: Ginger (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger (500 mg ginger powder, twice a day for 3 days)
Study: 21609911
Drug: Betahistine dihydrochloride
Normalized name: Betahistine Dihydrochloride
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine dihydrochloride treatment after Epley's maneuver (EM)
Study: 21609911
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment with betahistine after EM)
Study: 18313995
Drug: Oseltamivir phosphate
Normalized name: Oseltamivir Phosphate
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oseltamivir phosphate preparation 1
Study: 18313995
Drug: Oseltamivir phosphate
Normalized name: Oseltamivir Phosphate
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oseltamivir phosphate preparation 2
Study: 10319352
Drug: Treatment (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (three different methods)
Study: 10319352
Drug: Control (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (16 patients observed without treatment)
Study: 9172005
Drug: Test preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test preparation A (furosemide, 500 mg)
Study: 9172005
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation B (furosemide, 500 mg)
Study: 6398127
Drug: Methylprednisolone (MPN)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (MPN) 375 mg
Study: 6398127
Drug: Low-dose metoclopramide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose metoclopramide (MCP) 60 mg
Study: 28988340
Drug: Core decompression
Normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Core decompression plus saline injection
Study: 26338095
Drug: Tabalumab 120
Normalized name: Tabalumab
DrugBank: Tabalumab (DB11657)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tabalumab 120 mg every two weeks (120 Q2W)
Study: 26338095
Drug: Tabalumab 120
Normalized name: Tabalumab
DrugBank: Tabalumab (DB11657)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tabalumab 120 mg every four weeks (120 Q4W)
Study: 26338095
Drug: Tabalumab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tabalumab (both dosing regimens)
Study: 16925195
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg intravenous ketorolac (Toradol), 0.25% subcutaneous bupivacaine (Marcaine) with epinephrine along the incision, and 0.25% bupivacaine in the rectus fascia
Study: 1387778
Drug: Inocoterone 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inocoterone 10% solution
Study: 30357272
Drug: Recombinant alkaline
Normalized name: Human recombinant alkaline phosphatase
DrugBank: Recombinant human alkaline phosphatase (DB17672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant alkaline phosphatase 1.6 mg/kg
Study: 30357272
Drug: Recombinant alkaline
Normalized name: Human recombinant alkaline phosphatase
DrugBank: Recombinant human alkaline phosphatase (DB17672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant alkaline phosphatase 0.4 mg/kg
Study: 30357272
Drug: Recombinant alkaline
Normalized name: Human recombinant alkaline phosphatase
DrugBank: Recombinant human alkaline phosphatase (DB17672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant alkaline phosphatase 0.8 mg/kg
Study: 23390781
Drug: Combination 5-fluoruracil
Normalized name: 1-(β-D-5-desoxyribofuranoxyl)-5-fluoruracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination 5-fluoruracil (5-FU) with cisplatinum
Study: 16237467
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for gastric cancer
Study: 11888754
Drug: Metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 100 mg/24 h P.O. + 2x0.5 mg digoxin IV on the operating day + digoxin 0.25 mg P.O. + metoprolol 100 mg P.O. on the first postoperative day until discharge
Study: 11888754
Drug: Amiodarone 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone 1200 mg IV/24 h (300 mg bolus dose/1 h post-operation, then 450 mg/24 h IV and 600 mg/day P.O. until discharge)
Study: 8597006
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CyA) at 2.5 mg/kg/d
Study: 8597006
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CyA) at 5.0 mg/kg/d
Study: 29921405
Drug: Automatic reposition
Normalized name: AMMONIA,AROMATIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automatic reposition treatment
Study: 29921405
Drug: Manual reposition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual reposition treatment
Study: 26838074
Drug: XueBiJing injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: XueBiJing injection (intravenous infusion)
Study: 17172550
Drug: Intensive traditional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive traditional therapy
Study: 15678729
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate infusion (5 mg kg(‐1) bolus followed by 500 mg h(‐1) infusion for 24 h)
Study: 15678729
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (saline infusion in the same volumes for 24 h)
Study: 420135
Drug: Nutritional supplementation
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplementation (155 cal and 20 g of protein per day)
Study: 21998287
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for early syphilis
Study: 26108088
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate nasal spray (FPNS) 200 mcg once daily
Study: 23648948
Drug: BSS+ (Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: BSS+ (Behavioral Support Sessions plus bupropion therapy)
Study: 19402296
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D injection (600,000 IU)
Study: 17367443
Drug: Topical verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical verapamil hydrochloride 15% gel applied twice daily for 3 months, followed by open label for 6 months.
Study: 9039201
Drug: Butenafine 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butenafine 1% cream applied once daily for 2 weeks
Study: 9039201
Drug: Vehicle control
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle control applied once daily for 2 weeks
Study: 27306272
Drug: Group Cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Cognitive Behavioral Therapy for Insomnia (GT)
Study: 27306272
Drug: Internet Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet Cognitive Behavioral Therapy for Insomnia (IT)
Study: 28555208
Drug: One-piece implants
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-piece implants (OPI)
Study: 28555208
Drug: Two-piece implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-piece implants (TPI)
Study: 1579326
Drug: Group I
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I (missing pills on days 1-4)
Study: 1579326
Drug: Group II
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II (missing pills on days 3-6)
Study: 1579326
Drug: Group III
Normalized name: Corticosteroids, potent (group III)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group III (missing pills on days 6-9)
Study: 31309643
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day sesamin supplement
Study: 27461767
Drug: TIVA0 (manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIVA0 (manual infusion guided by clinical signs)
Study: 27461767
Drug: TIVABIS (BIS-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIVABIS (BIS-guided infusion)
Study: 27461767
Drug: TCI KBIS
Normalized name: adenovirus type 7 vaccine live
DrugBank: Adenovirus type 7 vaccine live (DB14685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCI KBIS (BIS-guided target controlled infusion with Kataria model)
Study: 27461767
Drug: TCI SBIS
Normalized name: adenovirus type 7 vaccine live
DrugBank: Adenovirus type 7 vaccine live (DB14685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCI SBIS (BIS-guided target controlled infusion with Schnider model)
Study: 24528939
Drug: HPLC diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPLC diet (very low carbohydrate, 22 g/d)
Study: 24528939
Drug: HPMC diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPMC diet (moderate carbohydrate, 182 g/d)
Study: 16268973
Drug: Gabapentin 300
Normalized name: gabapentin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 300 mg/day and then 600 mg/day
Study: 10402403
Drug: rec-FSH (Gonal-F,
Approvals — FDA: no, EMA: no, PMDA: no
Description: rec-FSH (Gonal-F, Serono) at a fixed dose of 150 IU/day for 3 days
Study: 10402403
Drug: rec-FSH (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: rec-FSH (150 IU/daily) continued until follicles were 10 mm in diameter, aspiration performed 72 h later
Study: 7554064
Drug: 300 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 g/day cooked Brussels sprouts
Study: 547122
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of scopolamine and physostigmine
Study: 28093928
Drug: Functional electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Functional electrical stimulation therapy
Study: 26346300
Drug: roxithromycin 300
Normalized name: roxithromycin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxithromycin 300 mg daily and doxycycline 100 mg daily
Study: 26346300
Drug: roxithromycin 300
Normalized name: roxithromycin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxithromycin 300 mg daily
Study: 16435344
Drug: Extracorporeal shockwave
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shockwave therapy (ESWT) with approximately 3,800 total shock waves, total energy delivery of 1,300 mJ/mm(2) in a single session
Study: 14755147
Drug: Procaine 2
Normalized name: procaine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaine 2 g/24 h by continuous intravenous infusion
Study: 14755147
Drug: Pentazocine 30
Normalized name: pentazocine 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine 30 mg every 6 h as a bolus intravenous injection